Adalimumab, Infliximab and Etanercept Biosimilars Market Growth Trajectory Through 2024-2033

Spread the love

The Adalimumab, Infliximab and Etanercept Biosimilars by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Adalimumab, Infliximab and Etanercept Biosimilars Market:

https://www.thebusinessresearchcompany.com/report/adalimumab-infliximab-and-etanercept-biosimilar-global-market-report

According to The Business Research Company’s Adalimumab, Infliximab and Etanercept Biosimilars, The adalimumab, infliximab and etanercept biosimilars market size has grown exponentially in recent years. It will grow from $3.67 billion in 2023 to $4.41 billion in 2024 at a compound annual growth rate (CAGR) of 20.3%. The growth in the historic period can be attributed to increased healthcare expenditure, regulatory changes, regulatory changes, government initiatives and rising healthcare costs..

The adalimumab, infliximab and etanercept biosimilars market size is expected to see rapid growth in the next few years. It will grow to $6.79 billion in 2028 at a compound annual growth rate (CAGR) of 11.4%. The growth in the forecast period can be attributed to a rise in healthcare expenditure, aging population and an increase in healthcare access will drive market growth. . Major trends in the forecast period include focus on launching new products, focus on mergers and acquisitions, focus on establishing strategic partnerships and focus on increasing investments..

The patent expiration of branded drugs allows biosimilars to enter the adalimumab, infliximab, and etanercept biosimilars market. For instance, in the United States, the FDA approved inflectra, developed by Hospira (a Pfizer Inc. company), for the treatment of various autoimmune diseases such as rheumatoid arthritis, adult ulcerative colitis, and plaque psoriasis, after the patent expiry of the branded drug Remicade. Similarly, Amgen’s Enbrel had its patent expire in the EU, and with the expiry of the patent, Benepali (a biosimilar of Enbrel) was approved by the European Commission. Humira’s patent expired, and its biosimilars were made available on the market. The FDA has recently (July 2020) approved Hulio, the sixth biosimilar of Humira. Therefore, the patent expiry of branded biologic drugs such as Humira, Enbrel, and Remicade will drive the adalimumab, infliximab, and etanercept biosimilars market demand.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=3473&type=smp

The adalimumab, infliximab and etanercept biosimilars market covered in this report is segmented –

1) By Product: Adalimumab Biosimilars, Infliximab Biosimilars, Cipleumab

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By Application: Crohn’s Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis, Other Applications

The brand-name versions of biosimilar drugs have high costs, which are now being replaced with biosimilar versions upon their patent’s expiry. The cost of branded biological drugs has almost doubled in recent years. For instance, the cost of Humira, the top-selling drug, increased to more than $72,000 in 2020. The shift to low-cost biosimilar drugs is mainly because there are no clinically relevant differences in safety and efficacy between the biosimilars and the original biologics. The Danish health care system switched almost entirely to adalimumab biosimilars after the patent on the original adalimumab product, Humira. The switch to biosimilars led to an 82% decrease in costs for the medication.

The adalimumab, infliximab and etanercept biosimilars market report table of contents includes:

Executive Summary
Adalimumab, Infliximab and Etanercept Biosimilars Market Characteristics
Adalimumab, Infliximab and Etanercept Biosimilars Market Trends And Strategies
Adalimumab, Infliximab and Etanercept Biosimilars Market – Macro Economic Scenario
Global Adalimumab, Infliximab and Etanercept Biosimilars Market Size and Growth

Global Adalimumab, Infliximab and Etanercept Biosimilars Market Competitive Benchmarking
Global Adalimumab, Infliximab and Etanercept Biosimilars Market Competitive Dashboard
Key Mergers And Acquisitions In The Adalimumab, Infliximab and Etanercept Biosimilars Market
Adalimumab, Infliximab and Etanercept Biosimilars Market Future Outlook and Potential Analysis
Appendix

Top Major Players: